Bourgeon Capital Management LLC Cuts Stock Position in Citigroup Inc. $C

Bourgeon Capital Management LLC cut its stake in shares of Citigroup Inc. (NYSE:CFree Report) by 9.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 122,690 shares of the company’s stock after selling 12,675 shares during the quarter. Citigroup accounts for approximately 2.3% of Bourgeon Capital Management LLC’s holdings, making the stock its 18th biggest position. Bourgeon Capital Management LLC’s holdings in Citigroup were worth $14,317,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wolff Wiese Magana LLC boosted its holdings in shares of Citigroup by 87.6% in the third quarter. Wolff Wiese Magana LLC now owns 257 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. Dunhill Financial LLC raised its holdings in Citigroup by 92.2% during the third quarter. Dunhill Financial LLC now owns 319 shares of the company’s stock worth $32,000 after purchasing an additional 153 shares in the last quarter. Guerra Advisors Inc purchased a new position in Citigroup during the third quarter worth about $33,000. Howard Hughes Medical Institute acquired a new stake in Citigroup in the second quarter valued at about $34,000. Finally, Capital A Wealth Management LLC purchased a new stake in Citigroup in the 2nd quarter valued at approximately $38,000. 71.72% of the stock is currently owned by hedge funds and other institutional investors.

Citigroup Stock Performance

Shares of C stock opened at $113.36 on Wednesday. The stock has a fifty day moving average price of $112.68 and a 200 day moving average price of $108.36. The company has a debt-to-equity ratio of 1.63, a quick ratio of 1.00 and a current ratio of 1.00. The stock has a market cap of $198.31 billion, a PE ratio of 16.26, a P/E/G ratio of 0.69 and a beta of 1.17. Citigroup Inc. has a 1 year low of $55.51 and a 1 year high of $125.16.

Citigroup (NYSE:CGet Free Report) last posted its earnings results on Wednesday, January 14th. The company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.65 by $0.16. The company had revenue of $19.87 billion for the quarter, compared to analyst estimates of $20.99 billion. Citigroup had a return on equity of 8.28% and a net margin of 8.50%.Citigroup’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.34 earnings per share. Sell-side analysts forecast that Citigroup Inc. will post 7.53 earnings per share for the current fiscal year.

Citigroup Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Monday, February 2nd were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 2.1%. The ex-dividend date was Monday, February 2nd. Citigroup’s dividend payout ratio (DPR) is 34.43%.

Insiders Place Their Bets

In other Citigroup news, insider Cantu Ernesto Torres sold 43,173 shares of Citigroup stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $111.09, for a total transaction of $4,796,088.57. Following the completion of the transaction, the insider owned 45,835 shares in the company, valued at approximately $5,091,810.15. The trade was a 48.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.08% of the company’s stock.

Analyst Upgrades and Downgrades

C has been the topic of several recent analyst reports. Wolfe Research reiterated an “outperform” rating and set a $141.00 target price on shares of Citigroup in a research report on Wednesday, January 7th. Royal Bank Of Canada restated an “outperform” rating and issued a $121.00 price target on shares of Citigroup in a research note on Thursday, January 15th. Wells Fargo & Company set a $150.00 price objective on Citigroup in a report on Monday, January 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of Citigroup in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group began coverage on Citigroup in a report on Thursday, March 26th. They issued a “buy” rating and a $135.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $127.00.

Check Out Our Latest Research Report on Citigroup

Key Stories Impacting Citigroup

Here are the key news stories impacting Citigroup this week:

  • Positive Sentiment: Market rumors that Citigroup was weighing a U.S. regional‑bank acquisition sparked a selloff but the bank publicly called the reports baseless; the denial and management’s reaffirmation of its organic‑growth strategy helped calm buyers and likely contributed to the rebound in the share price. QuiverQuant: Citigroup Stock Opinions
  • Positive Sentiment: Analyst coverage remains constructive overall: the consensus of recent analyst notes shows multiple buy/overweight ratings and a median 12‑month target near ~$131, providing a supportive research backdrop even as price targets are being adjusted. (This helps explain why dips have found buyers.) QuiverQuant: Analyst & target summary
  • Neutral Sentiment: Press reports note management is exploring next strategic moves under CEO Jane Fraser — including speculative interest in regional deals — which could be growth‑positive long term but would bring execution and regulatory risk if pursued. The Star: Citigroup eyes regional bank deal
  • Neutral Sentiment: Small, technical disclosure: Citigroup group entities ceased to be substantial holders in Australia’s Mayne Pharma — a housekeeping/regulatory filing with negligible operational impact on Citi. TipRanks: Substantial holder notice
  • Negative Sentiment: Insider selling (multiple exec sales reported) and large institutional reductions disclosed in recent filings are a cautionary signal for some investors—these disclosures have been highlighted in market commentary and can amplify short‑term downside on weak news. QuiverQuant: Insider & institutional activity
  • Negative Sentiment: Oppenheimer trimmed its price target for Citigroup to $132 — a modest downtick that may temper upside for some investors and feed short‑term headlines, though the new target remains within the range of street estimates. AmericanBankingNews: Oppenheimer cuts target

Citigroup Company Profile

(Free Report)

Citigroup Inc is a global financial services company headquartered in New York City with roots tracing back to the City Bank of New York, founded in 1812. The modern Citigroup was created through the 1998 merger of Citicorp and Travelers Group and has since operated as a diversified bank holding company that provides a broad range of banking and financial products and services to consumers, corporations, governments and institutions worldwide.

Citi’s principal businesses include retail and commercial banking, credit card and consumer lending products, wealth management and private banking, and a full suite of institutional services.

See Also

Want to see what other hedge funds are holding C? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Citigroup Inc. (NYSE:CFree Report).

Institutional Ownership by Quarter for Citigroup (NYSE:C)

Receive News & Ratings for Citigroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citigroup and related companies with MarketBeat.com's FREE daily email newsletter.